Krystal Biotech's KB113 Shrinks 83.1% of Assessed Basal Cell Carcinoma Lesions in Gorlin Syndrome Pilot Study

Krystal Biotech reported regression in 83.1% of assessed basal cell carcinoma lesions with KB113 in a three-patient Gorlin syndrome pilot study. Non-injected lesions showed an 85.1% regression rate, providing preliminary evidence of an abscopal effect. Biopsies confirmed complete tumor clearance in one injected lesion from each patient. All reported adverse events were mild or moderate, transient and resolved during the study. Discussions with the FDA have begun on advanced clinical development of KB113 for Gorlin syndrome. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Krystal Biotech Inc. published the original content used to generate this news brief via (Ref. ID: 202610150700PRIMZONEFULLFEED9846076) on October 15, 2026, and is solely responsible for the information contained therein. (C)